Israeli biotech company TransAlgae has announced an exclusive business development collaboration agreement with Virbac, a French company and one of the leading animal health players worldwide. The companies have signed an exclusive collaboration agreement to develop an oral vaccine based on TransAlgae’s breakthrough technology. To date, effective and efficient oral delivery in animal health has been one of the veterinary sector’s biggest challenges. TransAlgae’s technology aims to solve this challenge by utilising microalgae to both produce and deliver the vaccine, replacing injected vaccines. The microalgae are produced without any antibiotics in a process that enables rapid, low-cost production that can be practiced anywhere on the globe.